Life Sciences

  • July 23, 2026

    J&J's Delays Should End $25M Asbestos Appeal, Builder Says

    A western Massachusetts real estate developer has asked a Connecticut appeals court to toss Johnson & Johnson's appeal of a $25 million asbestos cancer verdict in his favor, saying the company has yet to file an opening brief despite receiving five deadline extensions.

  • July 22, 2026

    J&J Talc Plaintiffs Must Back Up Cancer Link Or Risk MDL

    Plaintiffs alleging Johnson & Johnson's talcum powder products caused ovarian cancer must show they can offer expert opinions on the link between the disease and talc use or risk having their lawsuits tossed, a New Jersey federal judge ruled Wednesday.

  • July 22, 2026

    Late Emails Undercut BCBS Pricing Suit, Walgreens Says

    Walgreen Co. is urging an Illinois federal judge to again sanction a Blue Cross Blue Shield insurer and its subsidiary for allegedly failing to produce key email evidence the pharmacy retailer says "upends" the insurers' 6-year-old claim that it intentionally overcharged them for prescription drugs.

  • July 22, 2026

    Organ Network, Hospital Sued Over Racial Kidney Criteria

    A kidney disease patient launched a proposed class action in Washington federal court Tuesday accusing the United Network for Organ Sharing and Seattle hospital operator Swedish Health Services of using a flawed race-based adjustment when scoring kidney functioning, hindering Black patients' chances of getting a transplant for years.

  • July 22, 2026

    TransMedics Sheds Some Claims In Organ Transfer Biz Suit

    A Massachusetts federal judge on Tuesday significantly trimmed a proposed shareholder class action alleging that medical technology company TransMedics Inc. and its top brass made misleading statements about the success and cost-effectiveness of its organ donation products and services.

  • July 22, 2026

    Boston Scientific Settles With Stryker In Spine Device IP Fight

    Boston Scientific and Stryker Corp. have reached a settlement to resolve a case in New Jersey federal court over Stryker's alleged efforts to create a back pain device that infringed a Boston Scientific patent.

  • July 22, 2026

    Safety-Net Clinics Defend Insulin Suit Revival To Justices

    Safety-net healthcare providers urged the U.S. Supreme Court not to take on the revival of their proposed antitrust class action against Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing Wednesday that the Second Circuit's decision was based on neither mere trade group lobbying nor any kind of overcharge.

  • July 22, 2026

    Candid Health Wraps $120M Series D Funding Round

    Autonomous revenue cycle management platform Candid Health, advised by Lowenstein Sandler LLP, on Wednesday revealed that it raised $120 million in its latest funding round, marking a three-times increase in valuation over the San Francisco-based company's previous funding round in February 2025.

  • July 22, 2026

    Fed. Circ. Panel Stands By Invalidated Spinal Fusion IP

    The Federal Circuit on Wednesday said it won't rethink a panel's decision invalidating patent claims covering parts used to make expandable implant devices in spinal fusion surgeries that were the basis of a $9.5 million jury verdict against Life Spine Inc.

  • July 22, 2026

    2 Charged In Alleged $52.7M COVID-19 Tax Scheme

    Two men have been indicted in Pennsylvania on allegations that they participated in a multistate conspiracy to bilk the government out of $52.7 million in a COVID-19-related false tax return scheme, according to federal prosecutors.

  • July 22, 2026

    Squires Grants 4 IPRs, Issues No Discretionary Denials

    U.S. Patent and Trademark Office Director John Squires has granted four more petitions for inter partes review, bringing his institution rate to just shy of 30%.

  • July 22, 2026

    Goodwin, K&L Gates Steer $1.5B Repligen Gene Therapy Deal

    Repligen said Wednesday it will acquire BioLife Solutions in a cash-and-stock transaction valued at about $1.5 billion, expanding its presence in the fast-growing cell and gene therapy market, with Goodwin Procter LLP advising Repligen and K&L Gates LLP representing BioLife.

  • July 22, 2026

    Judge Skeptical Of Harm From Chinese Military Co. Label

    A D.C. federal judge on Wednesday appeared skeptical of a Chinese pharmaceutical company's claims that it has suffered irreparable damage from the U.S. Department of Defense's recommendation that it be designated a "Chinese military company."

  • July 22, 2026

    Gene Therapy Co. Inks Better Ch. 11 Financing Deal

    Sangamo Therapeutics on Wednesday told a Delaware bankruptcy judge it has negotiated new Chapter 11 financing that will provide the biotechnology company with more money at a lower interest rate and asked permission to take out the new loan.

  • July 22, 2026

    DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief

    The U.S. Department of Labor urged the Second Circuit to shut down a suit claiming drugmaker Bristol-Myers Squibb violated federal benefits law by offloading $2.6 billion in pension liabilities to a risky annuity provider, saying benefit plans stand to suffer if courts greenlight flimsy claims of injury.

  • July 22, 2026

    Trump Says 100% Tariff On Generic Drugs Coming In 2028

    Generic drugs imported into the U.S. will be hit with a tariff of 100% in 2028 and 200% in later years in an attempt to drive manufacturing into the country, President Donald Trump said on social media.

  • July 21, 2026

    DC Circ. Affirms HHS Authority Over 340B Rebate Plans

    The D.C. Circuit on Tuesday upheld a lower court's finding that U.S. Department of Health and Human Services has the authority to block or approve drugmakers' efforts to implement rebates instead of discounts under the 340B drug-pricing program.

  • July 21, 2026

    Economist Concedes Opioid Stats' Limits In Albertsons Trial

    Despite testifying that Albertsons pharmacy records suggest some opioids dispensed in Washington state had "red flags" for potential diversion from legitimate use, an economist for the Evergreen State conceded Tuesday that he can't point to "even a single pill dispensed by Albertsons" that was actually improperly diverted. 

  • July 21, 2026

    Full Fed. Circ. Won't Review Apple's ITC Loss Against Masimo

    The full slate of Federal Circuit judges will not reconsider a panel's determination that Apple has infringed Masimo Corp.'s blood oxygen monitor patents in a high-profile case that led to some Apple Watch imports being banned.

  • July 21, 2026

    Class Cert. In Avandia MDL Undone For Lacking Stats

    The Third Circuit undid class certification for a group of health plans claiming GlaxoSmithKline deceptively marketed its diabetes drug Avandia, with a panel majority ruling Tuesday the plans needed stronger statistical analysis to show links between the marketing, the revelation of side effects and a drop in sales.

  • July 21, 2026

    Invisalign Maker Align Keeps PTAB Wins At Fed. Circ.

    The Patent Trial and Appeal Board properly invalidated claims in two Dental Monitoring SAS orthodontia patents, the Federal Circuit affirmed Tuesday.

  • July 21, 2026

    States Dispute Drugmakers' Bid To Toss GLP-1 Antitrust Case

    The attorneys general of Texas and Louisiana pushed back on Tuesday against a bid from Novo Nordisk and Eli Lilly to duck a specialty pharmacy's antitrust case accusing the companies of blocking competition for GLP-1 medications.

  • July 21, 2026

    Thermo Fisher Says TRO Needed To Protect $8.9B Deal

    A Delaware Chancery Court judge said Tuesday he is still weighing whether to temporarily block a former Thermo Fisher Scientific Inc. executive from joining Fortrea Holdings Inc., signaling that the dispute turns on difficult questions about the scope of restrictive covenants while cautioning the parties not to assume how he will rule.

  • July 21, 2026

    Novo's False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry

    Pharmaceutical giant Novo Nordisk Inc. slapped rival Eli Lilly & Co. with a false advertising suit in New Jersey federal court Tuesday, calling a marketing campaign for the rival's weight loss drugs "deceptive" for "withholding critical scientific evidence" about newer GLP-1 formulations.

  • July 21, 2026

    Wyeth's Patent Loss Has Attys Focusing On Dosage

    The Federal Circuit's holding that a Pfizer unit's cancer treatment patents are invalid highlights the risk of including dosages in patents without sufficient proof that those dosages work, attorneys say.

Expert Analysis

  • Accelerated Psychedelic Therapy Pathways Require Caution

    Author Photo

    President Donald Trump's new executive order aiming to accelerate the approval of psychedelic drugs for the treatment of mental health disorders will likely bolster investigational psychedelic therapies, but parties within the psychedelic product supply chain will still need to prepare for potentially burdensome compliance requirements, say attorneys at Morgan Lewis.

  • Heppner Ruling Left AI Privilege Risk For Lawyers Unresolved

    Author Photo

    While a New York federal judge’s recent ruling in U.S. v. Heppner resolved a privilege question surrounding client-side artificial intelligence use, it did not address how to mitigate the risks that can arise when confidential information enters the operative context of an AI system used by an attorney, says Jianfei Chen at Quarles & Brady​​​​​​​.

  • How 10 Years Of Case Law Have Shaped The DTSA

    Author Photo

    As the Defend Trade Secrets Act reaches its 10th anniversary, attorneys at Ropes & Gray examine recent DTSA case law and highlight key takeaways regarding pleading requirements, damages and risk factors.

  • The Ethics And Practicalities Of Representing AI Agents

    Author Photo

    With autonomous artificial intelligence agents now able to take action without explicit instructions from — or the awareness of — their human owners, the bar must confront whether existing frameworks like informed consent and client privilege will be sufficient on the day an AI agent calls seeking counsel, say attorneys at Morrison Cohen.

  • Series

    Speed Jigsaw Puzzling Makes Me A Better Lawyer

    Author Photo

    My passion for speed puzzling — I can complete a 500-piece jigsaw puzzle in under 50 minutes — has sharpened my legal skills in more ways than one, with both disciplines requiring patience, precision and the ability to keep the bigger picture in mind while working through the details, says Tazia Statucki at Proskauer.

  • Opinion

    Congress Should Ax Privacy Bill For Not Shielding Consumers

    Author Photo

    The SECURE Data Act should be rejected because, despite Congress' claims, it would not meaningfully rein in data practices, but instead would weaken enforcement, eliminate stronger protections and prioritize data extraction over consumer protection and accountability, say attorneys at DiCello Levitt.

  • Suit's Dismissal Would Not Settle Gold Card Visa's Legality

    Author Photo

    The government’s recent assertion that the plaintiffs in American Association of University Professors v. Department of Homeland Security lack standing to challenge the Trump administration’s pay-to-play immigration program does not address whether an agency can deem a million-dollar gift evidence of eligibility for immigration benefits carefully defined by Congress, says Jun Li at Reid & Wise.

  • 2 AI Snafus Show Why Attys Can't Outsource Judgment

    Author Photo

    The recent incident involving Sullivan & Cromwell where citations in a filed motion were fabricated by artificial intelligence, as well as a punitive ruling from the Sixth Circuit in U.S. v. Farris, demonstrate that the obligation to supervise AI has belonged and always will belong to lawyers, says John Powell at the Kentucky School Boards Association.

  • Opinion

    Congress Must Repair USPTO's Inter Partes Review Process

    Author Photo

    To challenge recent changes to the inter partes review process issued by the U.S. Patent and Trademark Office, Congress must establish clear statutory guardrails, transparency and meaningful judicial review so that questionable patents receive proper scrutiny, say Sean Tu at the University of Alabama, Arti Rai at Duke University and Aaron Kesselheim at Harvard.

  • Previewing FDA Preapproval Access In Psychedelics EO

    Author Photo

    The second of two pathways for psychedelic drug access outlined in President Donald Trump's recent executive order constitutes an unprecedented expansion of the Right to Try Act, which could fundamentally alter the psychedelic access landscape while presenting significant regulatory, operational and legal challenges, say attorneys at Husch Blackwell.

  • NY's Growing Enviro Reg Framework Will Transform Projects

    Author Photo

    Three closely connected environmental rulemakings in New York state — concerning greenhouse gas reporting, remediation standards and amendments to the State Environmental Quality Review Act — have reached critical stages, and taken together, they will have major impacts on business operations, construction project timelines and transactional risk, say attorneys at Holland & Knight.

  • How 'Spillover' Effects Can Skew AI Securities Class Actions

    Author Photo

    Event study evidence is often central in securities litigation at class certification and beyond, but in an environment where earnings forecasts and statements can have spillover market implications, particularly when concerning artificial intelligence, the task of parsing out the price impact of news requires careful consideration, say Erik Johannesson, Olivia Wurgaft and Nguyet Nguyen at Brattle Group.

  • Previewing FDA National Priority Vouchers In Psychedelics EO

    Author Photo

    President Donald Trump's recent executive order on psychedelic drug access represents a watershed moment in federal drug policy, but its significance lies in two distinct regulatory pathways, the first being the Commissioner's National Priority Vouchers, which offer a significant opportunity to compress U.S. Food and Drug Administration review, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.